Compare Merck & Co., Inc. (MRK) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ProShares Ultra Semiconductors — how do they compare? Merck & Co., Inc. trades at $126.01 (market cap $307.25B), while ProShares Ultra Semiconductors trades at $90.17. The key difference: Merck & Co., Inc. pays a 2.73% dividend while ProShares Ultra Semiconductors pays none, and Merck & Co., Inc. is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| MRK | USD | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.52 | $113.53 |
52-Week Low | $77.60 | $39.58 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.
The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.
USD trades at $83.24, up 1.19% with bearish technical signals from moving averages. Key support lies at $80 with resistance at $85. The company announced a $0.14 dividend for H1-2026, payable June 30, 2026. Recent news highlights include coverage of semiconductor sector volatility and earnings from various firms, though specific financials for USD are not detailed in the provided data.
The outlook remains cautious due to bearish technical indicators and limited fundamental data. Investment opportunity hinges on upcoming financial disclosures and sector performance, while risks include market volatility and reliance on broader economic conditions affecting semiconductor and related industries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
